AUSTIN, Texas, Dec. 7, 2010 /PRNewswire-FirstCall/ -- Luminex Corporation (Nasdaq: LMNX) and One Lambda, Inc., the leading producer of transplant diagnostic products, have agreed to a long-term renewal of their 10-year strategic partnership aimed at developing platforms and technologies for human leukocyte antigen (HLA) typing and antibody screening for the organ transplantation market. Begun in 2000, their dedicated collaboration has resulted in the creation of innovative products that have made pre- and post-transplant diagnostics faster, and more cost-efficient.
"One Lambda and Luminex combined the power of Luminex's xMAP® Technology with One Lambda's expertise in HLA testing and organ transplantation to dramatically advance the care available to those undergoing transplants," said George Ayoub, president and CEO of One Lambda. "Our platforms have significantly enhanced healthcare providers' ability to care for organ transplant patients by delivering vital information that helps them to better match donors with recipients."
Effective diagnostics are essential in transplant medicine. HLA typing and antibody screening are critical in matching organ donors and organ recipients, minimizing rejection and maintaining transplant patients' long-term health following a transplant. This kind of testing can require screening a patient for hundreds of HLA markers and antibodies. One Lambda's dedication to innovation ensures their products are continually updated with the latest donor registry data and new DNA genotypes. The simplicity and flexibility of the xMAP Technology platform to analyze both nucleic acids and proteins has allowed One Lambda to enhance and expand their product menu.
"Luminex and One Lambda have set the standard for strategic partnership with our collaboration that has delivered new technology and transformed the practice of transplantation medicine," said Patrick J. Balthrop, president and CEO of Luminex. "One Lambda has an impressive history of innovation in the field of transplantation, and we expect that our work together will continue to deliver significant technology advances and market leadership into the next decade."
One Lambda adopted Luminex's xMAP Technology to create products that could reduce the cost and complexity of HLA typing and antibody screening. The xMAP platform, which allows multiple, simultaneous tests to be run on a single sample, proved to be an ideal fit for transplant testing. The flexible technology helped One Lambda to develop a range of assays that have streamlined transplant diagnostics. One Lambda's LABType® SSO and LABScreen® products can detect up to 500 HLA specificities in a single test, eliminating the need to run multiple tests. One Lambda's xMAP-based assays are used in more than 80 countries worldwide.
About One LambdaOne Lambda, Inc. is the worldwide leader in HLA typing and antibody detection assays. One Lambda is known for its commitment to quality, service, and innovation. One Lambda develops and distributes several lines of HLA typing and antibody detection tests utilizing serological, molecular, ELISA, flow, and Luminex xMAP technologies. One Lambda also manufactures laboratory instrumentation and computer software that are used to simplify and automate testing procedures and final test evaluations. For more information, please visit www.onelambda.com.
About Luminex CorporationLuminex Corporation develops, manufactures, and markets proprietary biological testing technologies with applications throughout the diagnostic and life sciences industries. The company's xMAP® multiplex solutions include an open-architecture, multi-analyte technology platform that delivers fast, accurate, and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics, and biomedical research, including the genomics and proteomics markets. The company's xMAP Technology is sold worldwide and is already in use in leading clinical laboratories, as well as major pharmaceutical, diagnostic, and biotechnology companies. Further information on Luminex Corporation or xMAP Technology can be obtained at www.luminexcorp.com.Contacts:One Lambda:James Keegan, 818.702.0042Chief Financial OfficerLuminex Investor Contact:Matthew Scalo, 512.219.8020 Sr. Director Investor Relations email@example.comLuminex Media Contact: Mimi Torrington, 512.219.8020Director of Marketing Communicationsmtorrington@luminexcorp.comAaron DeLucia, 512.241.2249 firstname.lastname@example.org
|SOURCE Luminex Corporation; One Lambda, Inc.|
Copyright©2010 PR Newswire.
All rights reserved